In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia

European Journal of Pharmacology

Volumn 637, Issue 1-3, 2010, Pages 155-161

  King, Andrew J ^a   Segreti, Jason A ^a   Larson, Kelly J ^a   Souers, Andrew J ^a   Kym, Philip R ^a   Reilly, Regina M ^a   Collins, Christine A ^a   Voorbach, Martin J ^a   Zhao, Gang ^a   Mittelstadt, Scott W ^a   Cox, Bryan F ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Animal model; Diacylglycerol acyltransferase; Postprandial hyperlipidemia; Triglycerides

Indexed keywords

A 922500; ACYLTRANSFERASE INHIBITOR; ANTILIPEMIC AGENT; CORN OIL; DIACYLGLYCEROL ACYLTRANSFERASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; HAMSTER; HYPERLIPIDEMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ACYL COENZYME A; ANIMALS; CARDIOVASCULAR DISEASES; CORN OIL; CRICETINAE; DIACYLGLYCEROL O-ACYLTRANSFERASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYPERLIPIDEMIAS; MALE; MICE; POSTPRANDIAL PERIOD; RATS; RISK FACTORS; RODENTIA; TRIGLYCERIDES;

EID: 77953293707     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.056     Document Type: Article

References (50)

1. Adeli K., Lewis G.F. Intestinal lipoprotein overproduction in insulin-resistant states. Current opinion in lipidology 2008, 19:221-228.
2. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Jama 2007, 298:309-316.
3. Boyajian R.A., Otis S.M. Atherogenic progression of carotid stenosis associates selectively with monocyte fraction in circulating leukocytes. European Journal of Neurology 2002, 9:307-310.
4. Brunzell J.D., Hazzard W.R., Porte D., Bierman E.L. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. The Journal of clinical investigation 1973, 52:1578-1585.
5. Buhman K.K., Smith S.J., Stone S.J., Repa J.J., Wong J.S., Knapp F.F., Burri B.J., Hamilton R.L., Abumrad N.A., Farese R.V. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. The Journal of biological chemistry 2002, 277:25474-25479.
6. Cases S., Smith S.J., Zheng Y.W., Myers H.M., Lear S.R., Sande E., Novak S., Collins C., Welch C.B., Lusis A.J., Erickson S.K., Farese R.V. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:13018-13023.
7. Cases S., Stone S.J., Zhou P., Yen E., Tow B., Lardizabal K.D., Voelker T., Farese R.V. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. The Journal of biological chemistry 2001, 276:38870-38876.
8. Caslake M.J., Packard C.J., Gaw A., Murray E., Griffin B.A., Vallance B.D., Shepherd J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993, 13:702-711.
9. Chen H.C., Smith S.J., Ladha Z., Jensen D.R., Ferreira L.D., Pulawa L.K., McGuire J.G., Pitas R.E., Eckel R.H., Farese R.V. Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. The Journal of clinical investigation 2002, 109:1049-1055.
10. Cohn J.S. Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?. Atherosclerosis 2008, 9:15-18.
11. Cohn J.S., McNamara J.R., Cohn S.D., Ordovas J.M., Schaefer E.J. Postprandial plasma lipoprotein changes in human subjects of different ages. Journal of lipid research 1988, 29:469-479.
12. Duez H., Pavlic M., Lewis G.F. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atherosclerosis 2008, 9:33-38.
13. Fujinami K., Kojima K., Aragane K., Kusunoki J. Postprandial hyperlipidemia in Zucker diabetic fatty fa/fa rats, an animal model of type II diabetes, and its amelioration by acyl-CoA:cholesterol acyltransferase inhibition. Japanese journal of pharmacology 2001, 86:127-129.
14. Gottsater A., Forsblad J., Matzsch T., Persson K., Ljungcrantz I., Ohlsson K., Lindgarde F. Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies. Journal of internal medicine 2002, 251:61-68.
15. Haffner S.M., Foster D.M., Kushwaha R.S., Hazzard W.R. Retarded chylomicron apolipoprotein-B catabolism in type 2 (non-insulin-dependent) diabetic subjects with lipaemia. Diabetologia 1984, 26:349-354.
16. Haidari M., Leung N., Mahbub F., Uffelman K.D., Kohen-Avramoglu R., Lewis G.F., Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. The Journal of biological chemistry 2002, 277:31646-31655.
17. Hsieh J., Hayashi A.A., Webb J., Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atherosclerosis 2008, 9:7-13.
18. Iovine C., Lilli S., Gentile A., Patti L., Di Marino L., Cipriano P., Riccardi G., Rivellese A.A. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. European journal of clinical investigation 2006, 36:560-565.
19. Iovine C., Vaccaro O., Gentile A., Romano G., Pisanti F., Riccardi G., Rivellese A.A. Post-prandial triglyceride profile in a population-based sample of Type 2 diabetic patients. Diabetologia 2004, 47:19-22.
20. King A.J., Segreti J.A., Larson K.J., Souers A.J., Kym P.R., Reilly R.M., Zhao G., Mittelstadt S.W., Cox B.F. Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. The Journal of pharmacology and experimental therapeutics 2009, 330:526-531.
21. Kolovou G.D., Kostakou P.M., Anagnostopoulou K.K., Cokkinos D.V. Therapeutic effects of fibrates in postprandial lipemia. Am J Cardiovasc Drugs 2008, 8:243-255.
22. Kowala M.C., Recce R., Beyer S., Gu C., Valentine M. Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 2000, 149:323-330.
23. Lamarche B., Rashid S., Lewis G.F. HDL metabolism in hypertriglyceridemic states: an overview. Clinica chimica acta; international journal of clinical chemistry 1999, 286:145-161.
24. Lamarche B., Uffelman K.D., Carpentier A., Cohn J.S., Steiner G., Barrett P.H., Lewis G.F. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. The Journal of clinical investigation 1999, 103:1191-1199.
25. Lewis G.F., Uffelman K., Naples M., Szeto L., Haidari M., Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology 2005, 146:247-255.
26. Mangat R., Su J., Scott P.G., Russell J.C., Vine D.F., Proctor S.D. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochemical Society transactions 2007, 35:477-481.
27. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama 2007, 298:299-308.
28. Plaisance E.P., Mestek M.L., Mahurin A.J., Taylor J.K., Moncada-Jimenez J., Grandjean P.W. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. The American journal of clinical nutrition 2008, 88:30-37.
29. Proctor S.D., Pabla C.K., Mamo J.C. Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 2000, 149:315-322.
30. Rader D.J., Dugi K.A. The endothelium and lipoproteins: insights from recent cell biology and animal studies. Seminars in thrombosis and hemostasis 2000, 26:521-528.
31. Rashid S., Uffelman K.D., Lewis G.F. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. Journal of diabetes and its complications 2002, 16:24-28.
32. Razani B., Chakravarthy M.V., Semenkovich C.F. Insulin resistance and atherosclerosis. Endocrinology and metabolism clinics of North America 2008, 37:603-621. viii.
33. Redgrave T.G. Chylomicrons in disease-future challenges Invited keynote address. Atherosclerosis 2008, 9:3-6.
34. Ridker P.M. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?. Clinical chemistry 2008, 54:11-13.
35. Rivellese A.A., De Natale C., Di Marino L., Patti L., Iovine C., Coppola S., Del Prato S., Riccardi G., Annuzzi G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. The Journal of clinical endocrinology and metabolism 2004, 89:2153-2159.
36. Russell J.C., Proctor S.D. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006, 15:318-330.
37. Shepherd J. Mechanism of action of fibrates. Postgraduate medical journal 1993, 69(Suppl 1):S34-S41.
38. Skalen K., Gustafsson M., Rydberg E.K., Hulten L.M., Wiklund O., Innerarity T.L., Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
39. Smith S.J., Cases S., Jensen D.R., Chen H.C., Sande E., Tow B., Sanan D.A., Raber J., Eckel R.H., Farese R.V. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nature genetics 2000, 25:87-90.
40. Stalenhoef A.F., Watts G.F. Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008. Atherosclerosis 2008, 9:1-2.
41. van Oostrom A.J., Alipour A., Sijmonsma T.P., Verseyden C., Dallinga-Thie G.M., Plokker H.W., Castro Cabezas M. Comparison of different methods to investigate postprandial lipaemia. The Netherlands journal of medicine 2009, 67:13-20.
42. Vine D.F., Takechi R., Russell J.C., Proctor S.D. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007, 190:282-290.
43. Wang P.R., Guo Q., Ippolito M., Wu M., Milot D., Ventre J., Doebber T., Wright S.D., Chao Y.S. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. European Journal of Pharmacology 2001, 427:285-293.
44. Warnick G.R., Nakajima K. Fasting versus nonfasting triglycerides: implications for laboratory measurements. Clinical chemistry 2008, 54:14-16.
45. Weiss E.P., Fields D.A., Mittendorfer B., Haverkort M.A., Klein S. Reproducibility of postprandial lipemia tests and validity of an abbreviated 4-h test. Metabolism: clinical and experimental 2008, 57:1479-1485.
46. Yen C.L., Stone S.J., Koliwad S., Harris C., Farese R.V. Thematic Review Series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. Journal of lipid research 2008, 49:2283-2301.
47. Yu K.C., Cooper A.D. Postprandial lipoproteins and atherosclerosis. Frontiers in Bioscience 2001, 6:D332-D354.
48. Zhao G., Souers A.J., Voorbach M., Falls H.D., Droz B., Brodjian S., Lau Y.Y., Iyengar R.R., Gao J., Judd A.S., Wagaw S.H., Ravn M.M., Engstrom K.M., Lynch J.K., Mulhern M.M., Freeman J., Dayton B.D., Wang X., Grihalde N., Fry D., Beno D.W., Marsh K.C., Su Z., Diaz G.J., Collins C.A., Sham H., Reilly R.M., Brune M.E., Kym P.R. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. Journal of medicinal chemistry 2008, 51:380-383.
49. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
50. Zsigmond E., Fuke Y., Li L., Kobayashi K., Chan L. Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: the role of apoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro. Journal of lipid research 1998, 39:1852-1861.